Hopes rise over Pasteur crisis  by Gross, Michael
So researchers who would prefer
to work with non-pathogens may
be tempted by the availability of
funds to focus on pathogens and
submit grant proposals to a
biodefence programme.
But this too has financial
implications, because dangerous
organisms can be investigated
only within expensive, high
containment facilities. Moreover,
there is considerably less existing
knowledge to build upon in the
case of most pathogens than
exists for familiar organisms.
Enserink and Kaiser cite as one
instance a microbiologist at the
University of Wisconsin, Madison.
Patricia Kiley is contemplating
switching her work on bacterial
sensing of oxygen levels from
Escherichia coli, to a bioterrorism
agent. Although tempted to do so
in order to ‘get a shot at the
current US biodefence bonanza’,
she is likely to make slower
progress using an organism
whose physiology and genetics
are less familiar than one that has
been a key microbe in laboratories
for decades.
Anthony Fauci insists that the
number of NIAID grants for non-
defence bacterial physiology
projects has remained fairly
constant, at 120-150 annually,
over the past five years. He
concedes that the number may
have fallen at the other relevant
institute, the National Institute of
General Medical Sciences, though
this has probably reflected tighter
budgets generally.
One of the prime movers behind
the microbiologists’ letter is
Richard Ebright, a Howard Hughes
Institute investigator at Rutgers
University, New Jersey. He has
previously publicly criticised the
proliferation of laboratories
devoted to pathogens of potential
interest to terrorists, because of
the risks of accidental or deliberate
release. Ebright believes that the
same objectives could be achieved
by increasing research on related
but harmless organisms, and by
restricting work on putative
biological weapons to a few,
strictly controlled centres.
Bernard Dixon is the European editor
for the American Society for
Microbiology. 
Louis Pasteur set up the Institute
that bears his name in 1888, in
order to scale up the development
and use of his vaccine against
rabies, and to study the microbial
agents of infectious diseases. Built
on his pioneering work on
microbes and sterile working
conditions, the institute flourished
and became the seed for a world-
wide network of subsidiaries.
Within the first century of its
history, the institute produced
eight Nobel laureates. In recent
years, it has made major
contributions to the genome
sequences of microbes including
the tuberculosis pathogen.
The end of the 19th century saw
the Pasteur Institute undisputedly
at the forefront of microbiology
and public health. At the beginning
of the 21st century, however, the
institute has looked like it could do
with some renovation in body and
in spirit. When Philippe Kourilsky
took office as director general in
2000, he was determined to
modernize the institute. Now, in the
last year of his six-year tenure, he
admits that the institute has run
into a crisis which is partly his own
responsibility. On March 15, the
institute’s ‘parliament’, the
assembly of 100, met to install a
new council, which will have the
task to find a way out of the crisis
and possibly a new director.
General discomfort among the
researchers — who call
themselves ‘Pasteuriens’ — with
working conditions, the funding
situation, and the general
management style of Kourilsky’s
leadership had simmered for a few
years, when the provisions made
for the renovation of the buildings
on the main Pasteur campus in
central Paris, three kilometers
south-east of the Eiffel Tower,
brought the discontent to a head.
Two of the buildings are in
desperate need of renovation,
which has been planned to a
five-year schedule and has to be
started as soon as possible, as
parts of the location are said to be
in violation of existing laws
concerning workplaces. The
crunch point is the Duclaux
building on the West side of Dr
Roux street, where a total of 255
research staff need to be
evacuated to allow the work to
start. The management wanted to
move the researchers to an
industrial site at Fresnes, 10 km
south of the city centre, and sent
out letters informing researchers of
their displacement without
individual consultation.
The move to Fresnes was
fiercely opposed by most of the
researchers concerned, mainly on
grounds of poor public transport
accessibility and isolation from the
facilities in central Paris, which are
vital to Pasteur’s involvement in
public health. The lack of
consultation and response to
internal assessments that had
declared the move unnecessary
had further enraged the
Pasteuriens. To resolve the
conflict, the director of the 
UK’s National Institute for Medical
Research, John Skehel, and
administrator John Wills were
called in for an independent
appraisal of the situation. In a
detailed report dated February
17th, they confirmed that a
‘decanting’ of some research staff
would be necessary. They suggest,
however, that by refurbishing the
two wings of the building one after
the other, the number of
researchers to be displaced at one
time could be limited to 150, which
could be housed at the nearby
‘Biotop’ business park. A
Pasteurien who prefers not to be
named reckons that “after the
Skehel report, and given the
current climate, the direction has
decided to abort Fresnes... The
idea now is to move the whole
campus to Palaiseau,” a science
campus 20km south of Paris,
which already hosts numerous
educational and research
establishments. The final decision
will be left to the new council.
While the building questions can
probably be solved with a bit of
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The Pasteur Institute in Paris is
looking to move on from current
problems about its future.
Michael Gross reports.
common sense, the money and
management issues may be harder
to tackle. This part of the crisis
dates back to June 2004, when the
assembly refused to approve the
institute’s annual report because of
the impending financial troubles.
While Pasteur is a private non-
profit organisation that uses its
income from patents to fund
further research, its research is
intertwined with the public funding
bodies including CNRS and
INSERM, and thus it has also been
hit by the budget crisis that led to
the revolt of the researchers last
year (Curr. Biol. (2004) 14, R1031).
Following open protests outside
a council meeting in December,
the council collectively resigned in
January. Of its 20 members, only
the four sent by the government
remained. Hence the need to elect
16 new members on March 15.
In order to overcome the crisis
and open a new dialogue with his
research staff, Kourilsky took the
unprecedented step of opening a
chat room on the institute’s
intranet, where researchers could
anonymously put their questions
and complaints to him.
In the chat, Kourilsky admitted
that the institute was undergoing a
crisis, which he attributed to lack
of understanding between the
parties, and for which he assumed
shared responsibility. Replying to a
question about the loss of trust
between management and staff, he
said: “I have learned a lot from this
crisis. ... Re-establishing the
dialogue is very important to me.”
The coming weeks will show
whether this communications
exercise will be enough to win
back the trust of the research staff
and in particular the newly elected
council. This council represents a
credible new start for the institute,
and the national newspaper
Liberation headlined the following
day that “the tension decreases at
the Pasteur Institute”. 
So the researchers can go back
to work to make the institute as
successful in the 21st century as it
has been in the previous two.
Michael Gross is a science writer in
residence at the school of
crystallography, Birkbeck College,
University of London. He can be
contacted via his web page at 
www.proseandpassion.com
The Institute of Molecular
Pathology (IMP) in Vienna, Austria
has recently announced that Barry
Dickson will assume the position
of Director in January 2006.
Dickson will thus follow in the
footsteps of Max Birnstiel, the
Institute’s first Director, and Kim
Nasmyth, who will leave to head
the Department of Biochemistry at
the University of Oxford (see Curr.
Biol. 14, R452–R453). The
appointment was made following
the recommendation of an
international scientific
commission headed by Piet Borst
of Amsterdam.
Dickson was born in Australia
but after completing his
university studies in mathematics
and in biology he moved to
Zurich, Switzerland, where he
obtained his doctorate in the
group of Ernst Hafen, who was
studying the development of the
Drosophila eye. He then spent a
year and a half at the University
of California in Berkeley, working
with Corey Goodman on the
Drosophila central nervous
system. He continued this work
after his return to Zurich in 1996
and two years later he accepted
a position as Group Leader at the
IMP in Vienna, where he
remained until 2003.
During this period Dickson
addressed the question of how a
few thousand genes can direct
the assembly of complex
neuronal circuits, such as the
human brain. As a model system
he continued to use the fruit fly
Drosophila, which offers a
powerful set of genetic tools, and
he focused on identifying and
characterizing the ligands and
receptors that guide axons. The
axon pathway selection, reported
by his and Goodman’s groups,
represented a genuine
breakthrough in developmental
biology. Dickson was also able to
show that the regulated
intracellular trafficking of Robo
guidance receptors is
responsible for determining
which axons extend across the
midline of the central nervous
system; and more recently he has
also characterized an intracellular
signalling pathway that links
guidance receptors to the growth
cone cytoskeleton. Taken
together, this research has
played a major part in identifying
the signals that guide axons, in
explaining why various axons
differ in their response to these
signals, and in showing how the
signals guide axons to their final
positions.
In 2003 Dickson was appointed
Senior Scientist at the Institute
for Molecular Biotechnology
(IMBA) in Vienna (see Curr. Biol.
13, R39–R40). He used this short
move — the IMBA is immediately
adjacent to the IMP and the
latter institute still houses
Dickson’s lab — as an
opportunity to rethink the
scientific questions he wished to
tackle and the result was a
complete change in his scientific
direction. As he says, after nearly
ten years of working on
“someone else’s problem”
Magazine    
R231
New head in Vienna
Graham Tebb reports on the
appointment of the developmental
neurobiologist, Barry Dickson, as
the new director of the Institute of
Molecular Pathology in the
Austrian capital.
biologist, Barry Dickson, is crossing
town to become the next director of the
Institute of Molecular Pathology in
Vienna.
elucidation of the ‘Robo code’ for
‘Honoured’: The developmental neuro-
